Abstract: The present invention relates to the prevention and/or treatment of retinal dystrophy in a patient, including Leber congenital amaurosis (LCA).

Abstract: A method of determining health of a plant which method includes displaying, on a screen of an electronic display of a mobile computing device, a digital leaf colour chart with colours ranging from yellow green to dark green; displaying on the screen next to the digital leaf colour chart a white area on which a leaf of the plant is to be placed; receiving input to the mobile computing device from a user about which colour of the digital leaf colour chart that best matches the leaf placed on the white area; and the mobile computing device determining the plant health based on the received input.

Abstract: Various aspects of the present disclosure relate to a UE that receives a first configuration associated with a set of positioning reference signals, where the first configuration indicates a time and frequency resource for a positioning reference signal of the set of positioning reference signals. The UE also receives a second configuration that associates a positioning measurement of the positioning reference signal on the time and frequency resource, and receives one or more types of polarization associated with the first configuration and/or the second configuration. The UE also transmits a report indicating the one or more types of polarization associated with the positioning measurement of the positioning reference signal on the time and frequency resource.

Abstract: Apparatuses, methods, and systems are disclosed for location-aware beam selection. One method a communication device (i.e., a UE and/or gNB) includes mapping a set of beam signal characteristics to UE location information and storing said mapping to a Beam Fingerprint (“BFP”) database. The method includes identifying a UE location and selecting an optimal beam based using the UE location and the BFP database, said optimal beam being one of: a transmit beam and a receive beam.

Abstract: The present invention relates to the prevention and/or treatment of retinal disorders, such as cone dystrophies, cone-rod dystrophies, in particular Achromatopsia.

Abstract: There is provided a vector for treating retinal degeneration associated with Bardet-Biedl Syndrome (BBS), wherein the vector comprises a promoter operably linked to a BBS1 gene, wherein the promoter is selected from a rhodopsin kinase (RK) promoter, a cytomegalovirus immediate-early (CMV) promoter and a CAG promoter, and wherein the vector is selected from an AAV2/8 vector, an AAV2/7m8 vector and an AAV9 vector. Also disclosed is a pharmaceutical composition comprising the vector, and use of the vector in a method of treating retinal degeneration associated with BBS comprising administering a therapeutically effective amount of the vector to a patient suffering from BBS, wherein the vector is administered directly to the eye of the patient.

Abstract: The present invention relates to the prevention and/or treatment of retinal disorders, such as cone dystrophies, cone-rod dystrophies, in particular Achromatopsia.

Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.

Abstract: The present invention relates to the prevention and/or treatment of retinal disorders, such as cone dystrophies, cone-rod dystrophies, in particular Achromatopsia.

Abstract: The invention relates to the use of gene therapy vectors to improve vision by introducing into healthy rod photoreceptor cells of a patient suffering from cone photoreceptor dysfunction and/or degeneration a nucleic acid encoding a gene product that is light-sensitive and/or that modulates endogenous light-sensitive signalling in a photoreceptor cell, such that the range of light intensities to which the rod photoreceptor responds is extended and/or the speed at which the rod photoreceptor responds to light is increased

Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.

Abstract: The present invention relates to the prevention and/or treatment of retinal dystrophy in a patient, including Leber congenital amaurosis (LCA).

Abstract: The present invention relates to the identification of photoreceptors or cone photoreceptors in populations of cells. In particular the present invention relates to methods of identification of photoreceptors or cone photoreceptors and methods of isolating photoreceptors or cone photoreceptors. Photoreceptors or cone photoreceptors isolated by the methods of the present invention are useful for transplantation and the treatment of retinal dystrophies. Also claimed are human cell populations enriched for photoreceptors or cone photoreceptors and kits for identifying photoreceptors or cone photoreceptors.

Abstract: The present invention relates to the prevention and/or treatment of retinal dystrophyin a patient, including Leber congenital amaurosis (LCA).

Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.

Abstract: The invention relates to the use of gene therapy vectors to improve vision by introducing into healthy rod photoreceptor cells of a patient suffering from cone photoreceptor dysfunction and/or degeneration a nucleic acid encoding a gene product that is light-sensitive and/or that modulates endogenous light-sensitive signaling in a photoreceptor cell, such that the range of light intensities to which the rod photoreceptor responds is extended and/or the speed at which the rod photoreceptor responds to light is increased.

Abstract: The present invention relates to the prevention and/or treatment of retinal dystrophyin a patient, including Leber congenital amaurosis (LCA).

Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.

Abstract: The present invention relates to the treatment of ocular disease, specifically retinitis pigmentosa, by gene therapy using a modified version of the RPGR-ORF15 gene.